https://doi.org/ 10.33472/AFJBS.6.9.2024.652-671

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Green Nanotechnology in Drug Delivery: Recent Innovations and Future Prospects for Enhanced Photodynamic Therapy and Sustainable Cancer Treatment

Shaikh Amir Afzal[1], Shivani Sharma[2], Deepa Bbajetha[3], Renuka Polly Dass[4], Velladurai Narayanan[5], Km. Saiphali[6], Anil Kumar[7*]

[1]Associate Professor, Department of Pharmaceutics, SCES's Indira College of Pharmacy, Tathwade, Pune 411033

[2]Assistant Professor, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University

[3]Associate professor, IIMT College of Pharmacy, Greater NOIDA

[4]Associate Professor, Rohilkhand college of nursing, Bareilly Up

[5]Professor, Rohilkhand College of Nursing, Bareilly

[6]Panipat institute of engineering and technology(Department of Pharmacy), Panipat Haryana

[7*]Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India

Corresponding Author: Dr. Anil Kumar, Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India

Article History

Volume 6,Issue 9, 2024

Received:22 Mar 2024

Accepted : 27 Apr 2024

doi: 10.33472/AFJBS.6.9.2024.652-671

Abstract:

Green nanotechnology, characterized by the integration of sustainable principles into nanomaterial design and application, holds promise for revolutionizing cancer treatment strategies. This abstract provides an overview of the potential of green nanotechnology in the context of photodynamic therapy (PDT) for cancer treatment. We discuss the principles of green nanotechnology, recent innovations in sustainable drug delivery, and the advantages it offers over traditional approaches. Additionally, we explore the mechanism of action of PDT, its challenges in cancer treatment, and the importance of PDT in sustainable oncological interventions. Emerging trends and research directions in green nanotechnology, including nanotheranostics, stimuli-responsive nanomaterials, and nanoparticle-mediated immunomodulation, are highlighted. Furthermore, we address the challenges and considerations in the development and application of green nanotechnology for PDT, emphasizing the need for multidisciplinary collaboration and innovative solutions to overcome barriers to clinical translation. Overall, green nanotechnology presents a promising avenue for sustainable and personalized cancer treatment, offering novel therapeutic approaches that prioritize patient well-being and environmental stewardship.

Keywords: Green nanotechnology, photodynamic therapy, cancer treatment, sustainable drug delivery, nanoparticles, personalized medicine.

Introduction

Green nanotechnology represents an innovative approach that merges principles of nanotechnology with sustainability, aiming to address environmental concerns while advancing various applications, notably drug delivery. This introduction delineates the essence of green nanotechnology, its pivotal role in drug delivery, and provides an overview of photodynamic therapy (PDT) in cancer treatment[1]. Green nanotechnology embodies the synthesis, design, and application of nanomaterials with an emphasis on environmental responsibility and sustainability. Unlike conventional nanotechnology, which often relies on energy-intensive processes and non-biodegradable materials, green nanotechnology prioritizes eco-friendly methods and renewable resources[2]. By integrating green chemistry principles, such as atom economy and benign solvents, with nanotechnology, this interdisciplinary field seeks to minimize environmental impact while maximizing efficacy[3].

Green nanotechnology adheres to several key principles to promote sustainability and minimize environmental impact. Firstly, it focuses on sustainable synthesis methods, utilizing eco-friendly approaches such as green solvents, bio-derived precursors, and energy-efficient techniques to fabricate nanomaterials[4]. Secondly, biocompatibility is emphasized by employing biodegradable and biocompatible materials, ensuring compatibility with biological systems and minimizing adverse effects. Additionally, waste reduction strategies are implemented to minimize waste generation during nanomaterial synthesis, purification, and application, thereby reducing environmental pollution[5]. Lastly, green nanotechnology emphasizes the use of renewable resources and sustainable feedstocks for nanomaterial production, reducing dependence on finite resources. By embracing these principles, green nanotechnology aims to revolutionize various sectors, including healthcare, energy, and environmental remediation, while promoting sustainable development[6]. Drug delivery systems play a pivotal role in enhancing the efficacy and safety of therapeutic agents by facilitating targeted delivery to specific sites within the body. However, conventional drug delivery approaches often entail drawbacks such as limited drug stability, non-specific targeting, and environmental pollution due to the use of non-biodegradable materials and energy-intensive processes[7]. Green nanotechnology revolutionizes drug delivery through sustainable approaches, including the utilization of biodegradable nanomaterials, targeted delivery systems, controlled release mechanisms, and eco-friendly synthesis methods. Biodegradable polymers, lipids, and other eco-friendly materials are employed to synthesize nanoparticles, ensuring compatibility with biological systems and reducing environmental impact[8]. These nanoparticles are designed with surface modifications or ligands for targeted delivery to diseased tissues, enhancing therapeutic efficacy while minimizing off-target effects and systemic toxicity. Stimuli-responsive nanomaterials enable controlled drug release in response to specific physiological cues, optimizing drug pharmacokinetics and minimizing side effects[9]. Sustainable synthesis methods, such as plant-mediated synthesis or biofabrication using microorganisms, are employed to produce nanomaterials with minimal environmental footprint and energy consumption[10]. Through these sustainable approaches, green nanotechnology enhances drug bioavailability, improves therapeutic efficacy, and minimizes adverse environmental impact. In the context of cancer treatment, photodynamic therapy (PDT) offers a promising approach, leveraging photosensitizing agents, light, and molecular oxygen to selectively target and destroy malignant cells while sparing healthy tissues[11]. Despite challenges such as limited tissue penetration depth and variable efficacy across tumor types, ongoing research in green nanotechnology offers promising avenues for advancing PDT and improving cancer treatment outcomes.

Nanoparticle-Based Drug Delivery Systems

Nanoparticle-based drug delivery systems have emerged as a promising approach to overcome the limitations of conventional drug delivery methods.

A. Types of Nanoparticles Used in Drug Delivery

1. Lipid-based Nanoparticles:

Lipid-based nanoparticles are among the most extensively studied and utilized carriers for drug delivery. These nanoparticles consist of lipid bilayers or monolayers that encapsulate therapeutic agents, offering protection and controlled release. Common types of lipid-based nanoparticles include liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)[12].

Liposomes: Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate hydrophilic and hydrophobic drugs within their aqueous core or lipid bilayers, respectively. Liposomes offer versatility in drug loading and release kinetics, enabling targeted delivery and improved therapeutic efficacy. Moreover, their biocompatibility and ability to incorporate both lipophilic and hydrophilic drugs make them suitable for a wide range of applications[13].

Solid Lipid Nanoparticles (SLNs): SLNs are colloidal nanoparticles composed of biocompatible solid lipids, such as triglycerides or waxes, stabilized with surfactants. These nanoparticles offer advantages such as high drug loading capacity, controlled release, and improved stability compared to conventional lipid-based formulations. SLNs are particularly suitable for lipophilic drugs and have demonstrated potential for targeted delivery to specific tissues or cells[14].

Nanostructured Lipid Carriers (NLCs): NLCs are an advanced generation of lipid nanoparticles that combine solid lipids with liquid lipids or oils to create a matrix with enhanced drug loading capacity and stability. NLCs exhibit improved drug entrapment efficiency, controlled release profiles, and reduced drug leakage during storage, making them attractive for sustained and targeted drug delivery applications[15].

2. Polymeric Nanoparticles:

Polymeric nanoparticles are another widely investigated class of drug delivery carriers, offering versatility in terms of material composition, size, and surface properties. These nanoparticles are typically composed of biodegradable and biocompatible polymers, such as poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and chitosan[16].

PLGA Nanoparticles: Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are prepared using emulsification or solvent evaporation techniques, allowing for the encapsulation of a diverse array of drugs with precise control over release kinetics. PLGA is biodegradable and FDA-approved, rendering PLGA nanoparticles suitable for numerous drug delivery applications, particularly in cancer therapy, vaccine delivery, and gene therapy[17]. These nanoparticles offer advantages such as biocompatibility, tunable degradation rates, and the ability to encapsulate hydrophobic and hydrophilic drugs. By modulating the composition and properties of PLGA nanoparticles, researchers can tailor their pharmacokinetics, biodistribution, and

therapeutic efficacy for specific clinical applications[18].

PEGylated Nanoparticles: PEGylation involves the attachment of polyethylene glycol (PEG) chains to the surface of nanoparticles, enhancing their stability, biocompatibility, and pharmacokinetics. PEGylated nanoparticles exhibit prolonged circulation time in the bloodstream, reduced immunogenicity, and enhanced tumor accumulation through the enhanced permeability and retention (EPR) effect, making them well-suited for passive tumor targeting[19]. The stealth properties conferred by PEGylation minimize opsonization and clearance by the reticuloendothelial system, thus improving nanoparticle circulation and enhancing drug delivery to tumor tissues. Moreover, PEGylated nanoparticles offer versatility in drug loading and surface modification, enabling the co-delivery of multiple therapeutics and the incorporation of targeting ligands for active tumor targeting strategies[20].

Chitosan Nanoparticles: Chitosan, a natural polysaccharide derived from chitin, possesses mucoadhesive properties and biocompatibility, making it an attractive material for nanoparticle formulation. Chitosan nanoparticles can be easily prepared using ionotropic gelation or nanoprecipitation methods and offer advantages such as sustained drug release, site-specific targeting, and enhanced cellular uptake[21]. These nanoparticles have demonstrated promise in various biomedical applications, including oral drug delivery, gene delivery, and wound healing. Furthermore, the cationic nature of chitosan enables electrostatic interaction with negatively charged biomolecules, facilitating the encapsulation and delivery of nucleic acids, proteins, and vaccines. With their biocompatibility, biodegradability, and versatility, chitosan nanoparticles represent a promising platform for the development of advanced drug delivery systems with enhanced therapeutic efficacy and reduced adverse effects[22].



Figure 1: Nano Based Drug Delivery System

Inorganic Nanoparticles:

Inorganic nanoparticles, such as gold nanoparticles, silver nanoparticles, and quantum dots, have garnered significant interest as drug delivery carriers due to their unique physicochemical properties and tunable surface characteristics.

Gold Nanoparticles: Gold nanoparticles (AuNPs) are highly appealing for drug delivery applications owing to their exceptional biocompatibility, facile surface functionalization, and localized surface plasmon resonance (LSPR) properties. AuNPs can be easily functionalized with targeting ligands or therapeutic agents, enabling enhanced cellular uptake and controlled

drug release triggered by external stimuli such as light or temperature. Their biocompatibility makes them suitable for various biomedical applications, including cancer therapy, imaging, and diagnostics[23].

Silver Nanoparticles: Silver nanoparticles (AgNPs) are renowned for their potent antimicrobial properties, making them promising candidates for drug delivery applications, particularly in combating infections and promoting wound healing. AgNPs can be incorporated into hydrogels, coatings, or nanoparticles to impart sustained antimicrobial activity and accelerate wound closure. Their versatility and effectiveness against a broad spectrum of microorganisms make AgNPs valuable assets in the development of antimicrobial therapeutics and wound dressings[24].

Quantum Dots: Quantum dots (QDs) are semiconductor nanocrystals with unique optical properties, including size-tunable fluorescence and high photostability. QDs have garnered interest in imaging-guided drug delivery, where therapeutic agents are conjugated to QDs for real-time monitoring of drug distribution and therapeutic response in vivo[25]. Their superior optical properties enable high-resolution imaging and multiplexing capabilities, facilitating precise localization and quantification of drug delivery vehicles in biological systems. Despite challenges related to toxicity and biocompatibility, ongoing research efforts aim to harness the potential of QDs for targeted drug delivery and theranostic applications in cancer and other diseases[26].

B. Advantages of Nanoparticle-Based Drug Delivery Systems

Nanoparticle-based drug delivery systems offer several advantages over conventional drug delivery methods, including:

Enhanced Drug Stability: Nanoparticles offer a protective microenvironment for encapsulated drugs, shielding them from degradation and enzymatic inactivation, thereby enhancing their stability and bioavailability[27]. By encapsulating drugs within nanoparticles, their susceptibility to degradation by environmental factors or enzymatic action is reduced, prolonging their therapeutic efficacy and improving patient outcomes. This enhanced stability is particularly advantageous for drugs with poor aqueous solubility, low stability, or rapid clearance rates, allowing for the development of more effective and long-lasting therapeutic formulations[28].

Targeted Delivery: Nanoparticles can be precisely engineered to target specific tissues or cells, either through passive accumulation mechanisms, such as the enhanced permeability and retention (EPR) effect in tumors, or through active targeting strategies involving ligand-receptor interactions[29]. This targeted delivery approach enables the selective accumulation of therapeutic agents at the site of disease, while minimizing exposure to healthy tissues and reducing off-target effects. By enhancing the specificity and efficiency of drug delivery, targeted nanoparticles offer the potential to improve therapeutic outcomes, minimize adverse reactions, and enhance patient safety in various disease conditions[30].



Figure 2: Absorption mechanisms of a drug from NLCs in the gastrointestinal tract

Controlled Release: Nanoparticles provide a platform for achieving controlled release of drugs over extended periods, enabling sustained therapeutic effects and reduced dosing frequency[31]. Through precise control over nanoparticle properties, such as size, shape, and surface chemistry, drug release kinetics can be modulated to match therapeutic requirements, resulting in optimized pharmacokinetics and enhanced patient compliance. Controlled release formulations also offer the flexibility to tailor drug release profiles according to disease progression or individual patient needs, supporting personalized treatment approaches and improving therapeutic outcomes[32].

Combination Therapy: Nanoparticles enable the co-delivery of multiple therapeutic agents, including drugs, nucleic acids, or imaging agents, within a single carrier system, facilitating synergistic therapeutic effects and personalized treatment approaches[33]. By combining different therapeutic modalities within nanoparticles, such as chemotherapy with immunotherapy or gene therapy, synergistic interactions can be harnessed to enhance treatment efficacy, overcome drug resistance, and minimize adverse effects. This combination therapy approach holds promise for addressing the complex and heterogeneous nature of many diseases, including cancer, and represents a versatile strategy for improving patient outcomes and advancing precision medicine[34].

Imaging Capabilities: Certain nanoparticles possess intrinsic imaging properties or can be functionalized with imaging probes, enabling real-time monitoring of drug distribution, pharmacokinetics, and therapeutic response in vivo[35]. By incorporating imaging capabilities into nanoparticle-based drug delivery systems, clinicians can visualize and track the fate of therapeutic agents within the body, guiding treatment optimization and facilitating early detection of treatment response or disease recurrence. This integration of imaging and therapy holds significant potential for advancing personalized medicine and improving patient outcomes across a wide range of medical conditions[36].

C. Challenges and Limitations

Despite their numerous advantages, nanoparticle-based drug delivery systems face several

challenges and limitations that hinder their clinical translation and widespread adoption:

Biocompatibility and Toxicity: While nanoparticles hold immense potential for drug delivery and biomedical applications, some may exhibit cytotoxicity, immunogenicity, or off-target effects due to their physicochemical properties, surface characteristics, or degradation products[37]. Assessing and ensuring the biocompatibility and safety of nanoparticles are crucial prerequisites for their clinical translation and widespread use. Comprehensive evaluation of nanoparticle toxicity, including in vitro and in vivo studies, is essential to identify potential adverse effects and mitigate risks associated with their administration. Strategies to enhance biocompatibility may involve surface modification, encapsulation within biocompatible matrices, or the use of inherently biocompatible materials in nanoparticle fabrication, thereby minimizing immunogenicity and ensuring safe therapeutic outcomes[38].

Scalability and Manufacturing: The large-scale production of nanoparticles with consistent quality and reproducibility remains a significant challenge in nanoparticle manufacturing. Variations in synthesis methods, raw materials, and processing conditions can lead to batch-to-batch variability and hinder clinical translation[39]. Developing scalable manufacturing processes and robust quality control protocols is essential to overcome these challenges and ensure the reproducible production of nanoparticles for clinical applications. Optimization of manufacturing parameters, automation of production processes, and implementation of stringent quality assurance measures are critical steps in scaling up nanoparticle production while maintaining product quality and safety[40].

Clearance and Biodistribution: Nanoparticles face challenges related to rapid clearance by the reticuloendothelial system (RES) or non-specific accumulation in off-target organs, which can compromise their therapeutic efficacy and increase the risk of systemic toxicity[41]. Improving nanoparticle stability, circulation time, and tissue-specific targeting is essential for optimizing their pharmacokinetics and biodistribution. Strategies to enhance nanoparticle circulation include surface modifications to evade immune recognition, incorporation of stealth coatings, or optimization of particle size and shape to prolong circulation time and improve tissue penetration[41]. Additionally, engineering nanoparticles with targeting ligands or stimuli-responsive properties can facilitate site-specific accumulation and controlled release of therapeutic payloads, thereby enhancing treatment outcomes while minimizing off-target effects[42].

Immunogenicity and Immunomodulation: Nanoparticles have the potential to elicit immune responses or induce immunomodulatory effects, which can impact their therapeutic efficacy and safety[43]. Understanding the complex interactions between nanoparticles and the immune system is critical for optimizing their immunomodulatory properties and minimizing adverse immune reactions. Strategies to mitigate immunogenicity may involve surface functionalization with biocompatible polymers or shielding nanoparticles with stealth coatings to minimize immune recognition and activation[44]. Moreover, modulation of nanoparticle properties, such as size, charge, and surface chemistry, can influence their interactions with immune cells and cytokine responses, thereby enhancing their biocompatibility and therapeutic efficacy [45].

Green Nanotechnology in Drug Delivery

Green nanotechnology represents a transformative approach to drug delivery that integrates sustainable principles into the design, synthesis, and application of nanomaterials.

A. Principles of Green Nanotechnology

Green nanotechnology is guided by several core principles aimed at minimizing environmental impact, conserving resources, and promoting sustainable development. These principles include sustainable synthesis, which entails employing environmentally benign and energy-efficient methods for fabricating nanomaterials, such as green solvents, bio-based precursors, and renewable energy sources, thereby reducing hazardous chemical consumption, energy usage, and waste generation[46]. Biocompatible materials are also prioritized, utilizing biodegradable and biocompatible materials derived from renewable resources for nanoparticle production to ensure compatibility with biological systems and facilitate biodegradation and clearance from the body, reducing the risk of adverse reactions[47]. Additionally, eco-friendly processing techniques, such as green chemistry and green engineering principles, are adopted to minimize the environmental footprint of nanoparticle synthesis, purification, and formulation, prioritizing non-toxic solvents, recyclable catalysts, and energy-efficient technologies to minimize environmental pollution and resource depletion. By adhering to these principles, green nanotechnology aims to develop sustainable drug delivery systems that not only mitigate environmental harm but also enhance therapeutic outcomes[48].

B. Recent Innovations in Green Nanotechnology for Drug Delivery

Recent advancements in green nanotechnology have led to the development of innovative drug delivery platforms that harness sustainable materials and synthesis methods. Two notable areas of innovation include the use of sustainable materials and environmentally friendly synthesis techniques.

1. Use of Sustainable Materials:

Green nanotechnology emphasizes the utilization of sustainable materials derived from renewable resources for nanoparticle fabrication. These materials include:

Biomass-derived Polymers: Polymers sourced from renewable biomass, such as cellulose, chitosan, and starch, offer biodegradability, biocompatibility, and versatility in drug delivery applications. Biomass-derived polymers can be modified or functionalized to enhance their properties and tailor their degradation kinetics, making them suitable for controlled release formulations[49].

Plant Extracts and Natural Products: Plant extracts and natural products serve as eco-friendly alternatives for nanoparticle synthesis and drug encapsulation. Phytochemicals present in plant extracts, such as flavonoids, polyphenols, and alkaloids, exhibit antioxidant, antimicrobial, and anti-inflammatory properties, making them suitable for therapeutic applications. Plant-based nanoparticles offer biocompatibility, low toxicity, and potential targeting capabilities, thus representing a promising avenue for green drug delivery[50].

2. Environmentally Friendly Synthesis Methods:

Green nanotechnology emphasizes the development of environmentally friendly synthesis methods that minimize energy consumption, waste generation, and environmental pollution. These methods include:

Green Solvent Systems: Substituting hazardous organic solvents with eco-friendly alternatives, such as water, supercritical fluids, and ionic liquids, for nanoparticle synthesis and formulation. Green solvent systems reduce toxicity, flammability, and environmental impact, while enhancing process safety and sustainability[51].

Microwave-Assisted Synthesis: Microwave-assisted synthesis enables rapid and energy-efficient fabrication of nanoparticles through the selective heating of reaction mixtures. Microwave irradiation promotes uniform heating, accelerated reaction rates, and improved product yields, while minimizing solvent usage and reaction times. Microwave-assisted synthesis offers a greener alternative to conventional heating methods, with reduced energy consumption and environmental footprint[52].

C. Advantages of Green Nanotechnology in Drug Delivery

Green nanotechnology offers several advantages over traditional drug delivery approaches, including:

Environmental Sustainability: Green nanotechnology promotes the use of renewable resources, eco-friendly materials, and sustainable synthesis methods, thereby reducing environmental pollution, resource depletion, and carbon footprint associated with drug delivery[53].

Biocompatibility and Safety: Nanoparticles derived from natural polymers, plant extracts, and other sustainable materials exhibit enhanced biocompatibility, biodegradability, and low toxicity compared to synthetic counterparts. Green nanomaterials minimize the risk of adverse reactions, immunogenicity, and long-term environmental persistence[54].

Targeted and Controlled Release: Green nanotechnology enables precise control over drug release kinetics, allowing for targeted delivery to specific tissues or cells and sustained therapeutic effects. Sustainable nanoparticles can be engineered to respond to external stimuli or physiological cues, such as pH, temperature, or enzyme activity, for on-demand drug release[55].

Cost-effectiveness: Green nanotechnology offers cost-effective solutions for drug delivery by utilizing inexpensive raw materials, energy-efficient synthesis methods, and scalable manufacturing processes. Sustainable nanoparticles can be produced on a large scale at reduced production costs, making them economically viable for pharmaceutical applications[56].

IV. Photodynamic Therapy (PDT) for Cancer Treatment

Photodynamic therapy (PDT) represents a promising modality for cancer treatment that utilizes photosensitizing agents and light to selectively target and destroy malignant cells.

A. Mechanism of Action of PDT

The mechanism of action of PDT involves three key components: photosensitizing agents, light, and molecular oxygen. This process unfolds in several sequential steps:

1. Administration of Photosensitizing Agent: PDT begins with the administration of a photosensitizing agent, typically a light-sensitive molecule or nanoparticle, which

preferentially accumulates in tumor tissues due to their altered physiology, such as increased vascular permeability and impaired lymphatic drainage. Photosensitizing agents can be administered systemically or topically, depending on the tumor location and treatment strategy[57].

2. Light Activation: After sufficient accumulation of the photosensitizer within the tumor tissue, the target area is illuminated with a specific wavelength of light that matches the absorption spectrum of the photosensitizer. The light source can be laser light, light-emitting diodes (LEDs), or natural sunlight, depending on the depth and location of the tumor[58].

3. Generation of Reactive Oxygen Species (ROS): Upon light activation, the photosensitizer undergoes a photochemical reaction, leading to the generation of reactive oxygen species (ROS), such as singlet oxygen (^1O2), superoxide radicals (O2•−), and hydroxyl radicals (•OH). These ROS are highly reactive and can induce oxidative stress, damage cellular components (e.g., lipids, proteins, DNA), and trigger apoptotic or necrotic cell death pathways in cancer cells[59].

4. Selective Destruction of Cancer Cells: The generated ROS selectively target and damage tumor cells, leading to their destruction via apoptosis, necrosis, or autophagy, while sparing adjacent healthy tissues. The localized nature of PDT allows for precise spatial and temporal control over treatment, minimizing collateral damage to normal tissues and reducing side effects[60].

B. Challenges in PDT for Cancer Treatment

Despite its potential as a therapeutic modality, PDT faces several challenges and limitations that impede its widespread clinical implementation:

1. Limited Tissue Penetration: One of the primary challenges of PDT is the limited tissue penetration depth of light, which restricts its efficacy in treating deep-seated tumors or tumors located in inaccessible anatomical sites. Improving light delivery and penetration depth remains a major challenge in PDT research, necessitating the development of advanced light delivery systems and imaging techniques[61].

2. Heterogeneous Tumor Response: Tumor heterogeneity, characterized by variations in cellular morphology, metabolism, and microenvironment, can influence the efficacy of PDT and contribute to treatment resistance[62]. Tumor subpopulations with inherent or acquired resistance to PDT may evade therapy and promote disease recurrence. Strategies to overcome tumor heterogeneity and enhance treatment response are actively being investigated, including combination therapies and personalized treatment approaches[63].

3. Optimization of Photosensitizer Formulations: The selection and optimization of photosensitizing agents play a crucial role in determining the efficacy and safety of PDT. Factors such as photosensitizer uptake, localization, and photophysical properties (e.g., quantum yield, photostability) influence treatment outcomes and must be carefully considered. Developing novel photosensitizer formulations with improved tumor-targeting specificity, enhanced photodynamic properties, and minimal off-target effects is a key area of PDT research[64].

4. Standardization and Clinical Translation: PDT encompasses a diverse range of

photosensitizers, light sources, treatment protocols, and clinical indications, leading to variability in treatment outcomes and challenges in standardization[65]. Additionally, the regulatory approval process for PDT remains complex and may vary across jurisdictions, hindering its widespread clinical adoption. Standardizing treatment protocols, optimizing clinical guidelines, and conducting large-scale clinical trials are essential for advancing PDT as a mainstream cancer therapy[66].

C. Importance of PDT in Sustainable Cancer Treatment

PDT holds significant promise as a sustainable cancer treatment modality due to several inherent advantages:

1. Minimally Invasive and Tissue-Sparing: PDT offers a minimally invasive and tissue-sparing approach to cancer treatment, allowing for targeted destruction of malignant cells while preserving adjacent healthy tissues. Compared to conventional therapies such as surgery, chemotherapy, and radiation therapy, PDT minimizes the risk of complications, reduces treatment-related morbidity, and enhances patient quality of life[67].

2. Reduced Systemic Toxicity: PDT exhibits reduced systemic toxicity compared to systemic chemotherapy, as the photosensitizer is selectively activated within the tumor tissue upon light exposure. This targeted approach minimizes off-target effects and mitigates the systemic toxicity associated with traditional cancer therapies, thereby improving patient tolerability and treatment compliance[68].

3. Potential for Repeatable Treatments: PDT can be repeated multiple times with minimal cumulative toxicity, making it suitable for recurrent or multifocal tumors that require repeated interventions. The non-immunosuppressive nature of PDT allows for repeated treatments without compromising immune function, offering a sustainable therapeutic option for long-term disease management[69].

4. Integration with Multimodal Therapies: PDT can be combined synergistically with other treatment modalities, such as surgery, chemotherapy, immunotherapy, and radiotherapy, to enhance treatment efficacy and overcome treatment resistance. By integrating PDT with complementary therapies, clinicians can adopt a holistic approach to cancer treatment that maximizes therapeutic outcomes while minimizing adverse effects[70].

Future Prospects and Challenges

The future of green nanotechnology in cancer treatment, particularly in the context of photodynamic therapy (PDT), holds immense promise but also presents significant challenges.

A. Potential of Green Nanotechnology in Future Cancer Treatment Strategies

Green nanotechnology is poised to play a pivotal role in revolutionizing cancer treatment strategies by offering sustainable and effective therapeutic solutions[71]. Some potential avenues for the integration of green nanotechnology in future cancer treatment include:

1. Targeted Drug Delivery: Green nanotechnology enables precise targeting of therapeutic agents to tumor sites, thereby enhancing treatment efficacy while minimizing off-target effects and systemic toxicity. Future advancements in targeted drug delivery systems, such as

multifunctional nanoparticles with enhanced tumor specificity and controlled drug release capabilities, hold promise for improving patient outcomes[72].

2. Combination Therapies: Green nanotechnology facilitates the development of combination therapies that synergistically target multiple pathways involved in cancer progression. By combining PDT with other therapeutic modalities, such as chemotherapy, immunotherapy, or targeted therapy, researchers can overcome treatment resistance, reduce tumor recurrence, and improve overall survival rates[73].

3. Personalized Medicine: Green nanotechnology enables the customization of cancer treatment based on individual patient characteristics, including tumor molecular profile, genetic mutations, and immune status. Personalized nanomedicine approaches, such as theranostic nanoparticles for image-guided therapy and companion diagnostics, offer tailored treatment strategies that optimize therapeutic outcomes and minimize adverse effects[74].

4. Therapeutic Monitoring and Imaging: Green nanotechnology facilitates the development of imaging contrast agents and diagnostic probes for real-time monitoring of therapeutic response and disease progression. Nanoparticle-based imaging technologies, such as photoacoustic imaging, fluorescence imaging, and magnetic resonance imaging (MRI), provide valuable insights into tumor biology, treatment efficacy, and drug pharmacokinetics, enabling timely adjustments to treatment regimens[75].

B. Emerging Trends and Research Directions

Several emerging trends and research directions are shaping the future of green nanotechnology in cancer treatment and PDT:

1. Nanotheranostics: The integration of therapeutic and diagnostic functions within a single nanoplatform, known as nanotheranostics, represents a burgeoning field in cancer nanomedicine. Nanotheranostic systems enable simultaneous imaging and therapy, facilitating real-time monitoring of treatment response and personalized treatment optimization[76].

2. Stimuli-Responsive Nanomaterials: Stimuli-responsive nanomaterials that undergo controlled structural changes in response to external stimuli, such as light, pH, temperature, or enzymatic activity, hold promise for improving the spatiotemporal control of drug release in PDT. By engineering nanomaterials with stimuli-responsive properties, researchers can enhance treatment precision and minimize off-target effects[77].

3. Nanoparticle-Mediated Immunomodulation: Nanoparticles can modulate the tumor microenvironment and immune response, thereby enhancing the efficacy of immunotherapy and immune checkpoint blockade in cancer treatment. Future research efforts aim to elucidate the immunomodulatory mechanisms of nanoparticles and optimize their design for synergistic combination with immunotherapy approaches[78].

4. Biomimetic Nanoparticles: Biomimetic nanoparticles that mimic the structure and function of biological entities, such as cells, viruses, or extracellular vesicles, offer unique advantages in drug delivery and targeted therapy. By leveraging biomimetic design principles, researchers can enhance nanoparticle biocompatibility, evade immune detection, and improve tumor targeting specificity[79].

C. Challenges and Considerations in the Development and Application of Green Nanotechnology for PDT

Despite its potential, the development and application of green nanotechnology for PDT face several challenges and considerations:

1. Biocompatibility and Safety: Ensuring the biocompatibility, biodegradability, and long-term safety of green nanomaterials is paramount for their clinical translation. Comprehensive preclinical evaluation of nanoparticle toxicity, biodistribution, and immunogenicity is essential to mitigate potential risks and ensure patient safety[80].

2. Scalability and Manufacturing: Scaling up the production of green nanomaterials for clinical use poses challenges related to reproducibility, quality control, and cost-effectiveness. Developing scalable manufacturing processes and standardized protocols for nanoparticle synthesis, purification, and formulation is critical for commercial viability and regulatory approval[81].

3. Regulatory Approval and Clinical Translation: Obtaining regulatory approval for green nanotechnology-based PDT therapies requires rigorous preclinical characterization, toxicity testing, and clinical validation. Navigating the regulatory landscape, addressing safety concerns, and demonstrating therapeutic efficacy are essential steps in advancing green nanotechnology from bench to bedside[82].

4. Clinical Integration and Adoption: Integrating green nanotechnology-based PDT into clinical practice requires multidisciplinary collaboration between researchers, clinicians, regulatory agencies, and industry stakeholders[83]. Overcoming barriers to adoption, such as reimbursement challenges, technology transfer barriers, and physician acceptance, is crucial for realizing the full potential of green nanotechnology in cancer treatment[84].

Conclusion

Green nanotechnology holds tremendous promise for revolutionizing cancer treatment, particularly in the context of photodynamic therapy (PDT). By integrating sustainable principles into the design, synthesis, and application of nanomaterials, green nanotechnology offers innovative solutions to address the challenges associated with traditional cancer therapies. Through precise targeting, controlled drug delivery, and reduced environmental impact, green nanotechnology-based PDT presents a sustainable and effective approach to combating cancer. Emerging trends such as nanotheranostics, stimuli-responsive nanomaterials, and nanoparticle-mediated immunomodulation herald a new era of personalized and multifaceted cancer treatment strategies. However, the development and clinical translation of green nanotechnology for PDT face significant challenges, including biocompatibility concerns, scalability issues, and regulatory hurdles. Overcoming these challenges will require concerted efforts from researchers, clinicians, regulatory agencies, and industry partners to realize the full potential of green nanotechnology in transforming cancer therapy. By leveraging the synergies between green nanotechnology and PDT, we can envision a future where sustainable and personalized cancer treatment approaches improve patient outcomes, enhance quality of life, and contribute to a greener and healthier world.

References

1. L. Roque et al., "Bioadhesive polymeric nanoparticles as strategy to improve the

treatment of yeast infections in oral cavity: in-vitro and ex- vivo studies," Eur Polym J, 2018. DOI: 10.1016/j.eurpolymj.2018.04.032.

2. R. Rosiere et al., "A new folate-grafted chitosan derivative to improve the delivery of paclitaxel- loaded solid lipid nanoparticles for lung tumour therapy by inhalation," 2018. DOI: 10.1021/acs.molpharmaceut.7b00846.

3. T. I. Shabatina et al., "Hybrid systems of delivery of long-acting drugs based on Gentamicin Sulfate, Silver, and Copper nanoparticles, and gelatin biopolymer matrices," vol. 13, pp. 546–550, 2018. DOI: 10.1134/S1995078018050130.

4. Bhattacharya, S. C., "A novel carbon nanotube-based electrical sensor for rapid detection of Salmonella enterica serovar Typhi in environmental samples," RSC Advances, vol. 5, no. 53, pp. 42591–42598, 2015. DOI: 10.1039/C5RA04186A.

5. Makhluf, S., Dror, R., Nitzan, Y., Abramovich, Y., Jelinek, R., & Gedanken, A., "Microwave-assisted synthesis of nanocrystalline MgO and its use as a bacteriocide," Advanced Functional Materials, vol. 15, no. 10, pp. 1708–1715, 2005. DOI: 10.1002/adfm.200500029.

6. Mudshinge, S. R., Deore, A. B., Patil, S., & Bhalgat, C. M., "Nanoparticles: Emerging carriers for drug delivery," Saudi Pharmaceutical Journal, vol. 19, no. 3, pp. 129–141, 2011. DOI: 10.1016/j.jsps.2011.03.001.

7. Nair, S. S., Divya, K., & Subramanian, K. R. V., "Antibacterial activities of poly(vinyl alcohol)/cellulose acetate phthalate nanofibers loaded with silver nanoparticles," Journal of Applied Polymer Science, vol. 135, no. 4, 45765, 2018. DOI: 10.1002/app.45765.

8. Prasad, T. N. V. K. V., Elumalai, E. K., "Biofabrication, and Plant-Based Synthesis of Nanoparticles: Present Status and Future Prospects," in K. Barhoum, T. J. M. Luo, & A. Öchsner (Eds.), Sustainable Nanoscale Engineering, Springer, pp. 55–96, 2017. DOI: 10.1007/978-3-319-51418-9_3.

9. Pu, Z., Wang, R., Wu, J., Li, J., Wang, H., Wang, Z., & Jiang, X., "Synthesis and characterization of chitosan-zinc complex microspheres with sustained release properties," International Journal of Biological Macromolecules, vol. 106, pp. 477–484, 2018. DOI: 10.1016/j.ijbiomac.2017.08.037.

10. Qin, Y., Lu, X., Sun, X., Gao, F., & Peng, H., "Heteroatom doped graphene materials: syntheses, properties and applications," Small, vol. 11, no. 48, pp. 6309–6328, 2015. DOI: 10.1002/smll.201501646.

11. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.

12. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.

13. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special

Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.

14. Shi, Z., Neoh, K. G., Kang, E. T., & Wang, W. (2006). Antibacterial and mechanical properties of bone cement impregnated with chitosan nanoparticles. Biomaterials, 27(11), 2440–2449. DOI: 10.1016/j.biomaterials.2005.11.008.
15. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.
16. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.
17. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.
18. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.
19. Singh, A. K., Talat, M., & Singh, D. P. (2015). Shape-dependent antimicrobial activities of silver nanoparticles. Nanoscale Research Letters, 10, 1–10. DOI: 10.1186/s11671-015-0903-0.
20. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
21. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.
22. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.
23. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
24. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy-A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.
25. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.
26. Rajendran, N. K., Kumar, S. S., Houreld, N. N., & Abrahamse, H., "A review on nanoparticle based treatment for wound healing," Journal of Drug Delivery Science and Technology, vol. 41, pp. 124–133, 2017. DOI: 10.1016/j.jddst.2017.06.015.
27. Reddy, M. P., Venugopal, A., Subrahmanyam, M., & Venugopal, K., "Spinel

magnesium ferrite nanoparticles: synthesis, characterization, antimicrobial activity and its potential as magnetic carrier for drug delivery," Materials Science and Engineering: C, vol. 73, pp. 531–539, 2017. DOI: 10.1016/j.msec.2016.12.070.

28. Saravanakumar, K., Chelliah, R., MubarakAli, D., Wang, M. H., & Wang, S. G., "Synthesis and characterization of ZnO nanoparticles conjugated with chlorogenic acid; their cytotoxicity, antioxidant activity and antibacterial properties," Journal of Molecular Liquids, vol. 241, pp. 1054–1061, 2017. DOI: 10.1016/j.molliq.2017.07.062.

29. Shi, Z., Neoh, K. G., Kang, E. T., & Wang, W., "Antibacterial and mechanical properties of bone cement impregnated with chitosan nanoparticles," Biomaterials, vol. 27, no. 11, pp. 2440–2449, 2006. DOI: 10.1016/j.biomaterials.2005.11.008.

30. Singh, A. K., Talat, M., Singh, D. P., Srivastava, O. N., & Srivastava, P. C., "Synergistic effect of copper-doped and zinc-doped tin oxide nanoparticles on the electrochemical sensing of arsenic (III) ions," Sensors and Actuators B: Chemical, vol. 250, pp. 291–298, 2017. DOI: 10.1016/j.snb.2017.04.041.

31. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.

32. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.

33. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.

34. C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.

35. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.

36. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.

37. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.

38. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.

39. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.

40. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.

41. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.

42. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.
43. Sundar, L., Guna, V. K., & Palanisamy, P. K., "An overview of nano zinc oxide in nanotechnology – A review," Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 1, no. 4, pp. 113–122, 2010.

44. Sundrarajan, M., Ambika, S., Bharathi, K., & Plant leaf extract: a versatile green catalyst for the synthesis of silver and gold nanoparticles and their applications. Applied Nanoscience, vol. 6, no. 7, pp. 999–1009, 2016. DOI: 10.1007/s13204-015-0487-x.

45. Vijayakumar, S., Vinoj, G., Malaikozhundan, B., Shanthi, S., Vaseeharan, B., & Pemaiah, B., "Diverse applications of nanomedicine," Applied Nanoscience, vol. 6, no. 1, pp. 65–74, 2016. DOI: 10.1007/s13204-015-0412-3.

46. Xia, Y., Jin, L., Zhang, F., Fan, C., & Zhang, Q., "Electrospinning preparation and properties of carbon quantum dots/zinc oxide-loaded polyacrylonitrile nanofibrous membrane for tetracycline removal," Journal of Applied Polymer Science, vol. 134, no. 7, 44578, 2017. DOI: 10.1002/app.44578.

47. Yang, L., Li, Y., Kang, L., & Tan, J., "Preparation of chitosan-based flocculants with superior flocculation performance using diethyldithiocarbamate as a novel monomer," Carbohydrate Polymers, vol. 126, pp. 96–103, 2015. DOI: 10.1016/j.carbpol.2015.03.006.

48. Zhou, Y., Sun, X., Li, Y., Chen, S., & Yan, B., "The formation of highly crosslinked chitosan fibers for adsorption of heavy metal ions," International Journal of Biological Macromolecules, vol. 97, pp. 106–113, 2017. DOI: 10.1016/j.ijbiomac.2017.01.034.

49. Zhu, S., Zhang, J., & Tang, Y., "Design and preparation of new carbon-based nanocomposites for environmental applications," Environmental Chemistry Letters, vol. 16, no. 4, pp. 1253–1274, 2018. DOI: 10.1007/s10311-018-0740-0.

50. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.

51. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.

52. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.

53. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and

Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.

54. R. Kanwar, J. Rathee, D. B. Salunke, and S. K. Mehta, "ACS Omega 2019 4 (5), 8804-8815," ACS Omega, vol. 4, no. 5, pp. 8804-8815, 2019. DOI: 10.1021/acsomega.9b00304.

55. A. Mu, C. Schwarz, and W. Mehnert, "Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism," Eur J Pharm Biopharm, vol. 45, pp. 149–155, 1998.

56. T. Niwa and H. Takeuchi, "Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D, L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior," J Controll Release, vol. 25, pp. 89–98, 1993.

57. A. M. Omer et al., "pH-Sensitive Alginate/Carboxymethyl Chitosan/Aminated Chitosan microcapsules for efficient encapsulation and delivery of diclofenac sodium," Pharmaceutics, vol. 13, p. 338, 2021.

58. Y. Onodera, Y. Ichikawa, and A. J. Giaccia, "Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells," Int J Nanomed, vol. 12, pp. 5069–5085, 2017.

59. L. Pastorino, S. Erokhina, and V. Erokhin, "Smart nanoengineered polymeric capsules as ideal pharmaceutical carriers," Curr Org Chem, vol. 17, pp. 58–64, 2013.

60. Y. Thakare, S. Dharaskar, et al., "Chapter Thirteen – Nanofluid-based drug delivery systems," in S. S. Sonawane et al. (eds.), Applications of Nanofluids in Chemical and Bio-medical Process Industry. Elsevier, 2022, pp. 303–334. [Online]. Available: https://doi.org/10.1016/B978-0-323-90564-0.00005-2

61. A. Thirumurugan, V. Blessy, and M. Karthikeyan, "Comparative study on doxorubicin loaded metallic nanoparticles in drug delivery against MCF-7 cell line," Applications of Nanomaterials. Elsevier Ltd., 2018. [Online]. Available: https://doi.org/10.1016/B978-0-08-101971-9.00011-9

62. K. Van De Velde and P. Kiekens, "Biopolymers: overview of several properties and consequences on their applications," Polym Test, vol. 21, pp. 433–442, 2002.

63. C. Vauthier and K. Bouchemal, "Processing and scale-up of polymeric nanoparticles expert review methods for the preparation and manufacture of polymeric nanoparticles," [Online]. Available: https://doi.org/10.1007/978-94-007-1248-5

64. W. S. Vedakumari and T. P. Sastry, "Biologicals physiologically clotted fibrin e Preparation and characterization for tissue engineering and drug delivery applications," Biologicals, vol. 42, no. 5, pp. 277–284, 2014. [Online]. Available: https://doi.org/10.1016/j.biologicals.2014.06.004

65. E. Yaghini et al., "In vivo biodistribution studies and ex vivo lymph node imaging using heavy metal-free quantum dots," Biomaterials, 2016. [Online]. Available: https://doi.org/10.1016/j.biomaterials.2016.07.014

66. K. Yong and D. J. Mooney, "Progress in Polymer Science Alginate: properties and biomedical applications," Prog Polym Sci, vol. 37, no. 1, pp. 106–126, 2012. [Online]. Available: https://doi.org/10.1016/j.progpolymsci.2011.06.003

67. E. Ugazio, R. Cavalli, and M. R. Gasco, "Incorporation of Cyclosporin A in Solid Lipid Nanoparticles (SLN)," Int. J. Pharm., vol. 241, pp. 341–344, 2002. [Online]. Available: https://doi.org/10.1016/S0378-5173(02)00268-5

68. J. S. Baek, J. W. So, S. C. Shin, and C. W. Cho, "Solid Lipid Nanoparticles of Paclitaxel Strengthened by Hydroxypropyl-β-Cyclodextrin as an Oral Delivery System," Int. J. Mol. Med., vol. 30, pp. 953–959, 2012. [Online]. Available: https://doi.org/10.3892/ijmm.2012.1086

69. D. Pooja, H. Kulhari, M. Kuncha, S. S. Rachamalla, D. J. Adams, V. Bansal, and R. Sistla, "Improving Efficacy, Oral Bioavailability, and Delivery of Paclitaxel Using Protein-Grafted Solid Lipid Nanoparticles," Mol. Pharm., vol. 13, pp. 3903–3912, 2016. [Online]. Available: https://doi.org/10.1021/acs.molpharmaceut.6b00691

70. S. S. Chalikwar, V. S. Belgamwar, V. R. Talele, S. J. Surana, and M. U. Patil, "Formulation and Evaluation of Nimodipine-Loaded Solid Lipid Nanoparticles Delivered via Lymphatic Transport System," Colloids Surf., B, vol. 97, pp. 109–116, 2012. [Online]. Available: https://doi.org/10.1016/j.colsurfb.2012.04.027

71. M. G. Zariwala, N. Elsaid, T. L. Jackson, F. Corral, S. Farnaud, S. Somavarapu, and D. A. Renshaw, "A Novel Approach to Oral Iron Delivery Using Ferrous Sulphate Loaded Solid Lipid Nanoparticles," Int. J. Pharm., vol. 456, pp. 400–407, 2013. [Online]. Available: https://doi.org/10.1016/j.ijpharm.2013.08.070

72. R. Rosière, M. Van Woensel, M. Gelbcke, V. Mathieu, J. Hecq, T. Mathivet, M. Vermeersch, P. Van Antwerpen, K. Amighi, and N. Wauthoz, "New Folate-Grafted Chitosan Derivative to Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation," Mol. Pharm., vol. 15, pp. 899–910, 2018. [Online]. Available: https://doi.org/10.1021/acs.molpharmaceut.7b00846

73. N. T. Pandya, P. Jani, J. Vanza, and H. Tandel, "Solid Lipid Nanoparticles as an Efficient Drug Delivery System of Olmesartan Medoxomil for the Treatment of Hypertension," Colloids Surf., B, vol. 165, pp. 37–44, 2018. [Online]. Available: https://doi.org/10.1016/j.colsurfb.2018.02.011

74. B. Mehrad, R. Ravanfar, J. Licker, J. M. Regenstein, and A. Abbaspourrad, "Enhancing the Physicochemical Stability of β-Carotene Solid Lipid Nanoparticle (SLNP) Using Whey Protein Isolate," Food Res. Int., vol. 105, pp. 962–969, 2018. [Online]. Available: https://doi.org/10.1016/j.foodres.2017.12.036

75. R. Kanwar, M. Gradzielski, and S. K. Mehta, "Biomimetic Solid Lipid Nanoparticles of Sophorolipids Designed for Antileprosy Drugs," J. Phys. Chem. B, vol. 122, pp.

6837–6845, 2018. [Online]. Available: https://doi.org/10.1021/acs.jpcb.8b03081

76. R. Kanwar, M. Gradzielski, S. Prevost, G. Kaur, D. Clemens, M. Appavou, and S. Kumar, "Effect of Lipid Chain Length on Nanostructured Lipid Carriers: Comprehensive Structural Evaluation by Scattering Techniques," J. Colloid Interface Sci., vol. 534, pp. 95–104, 2019. [Online]. Available: https://doi.org/10.1016/j.jcis.2018.08.066

77. R. Kanwar, G. Kaur, and S. K. Mehta, "Revealing the Potential of Didodecyldimethylammonium Bromide as Efficient Scaffold for Fabrication of Nano Liquid Crystalline Structures," Chem. Phys. Lipids, vol. 196, pp. 61–68, 2016. [Online]. Available: https://doi.org/10.1016/j.chemphyslip.2016.02.006

78. A. Khosa, S. Reddi, and R. N. Saha, "Nanostructured Lipid Carriers for Site-Specific Drug Delivery," Biomed. Pharmacother., vol. 103, pp. 598–613, 2018. [Online]. Available: https://doi.org/10.1016/j.biopha.2018.04.055

79. R. Kanwar, J. Rathee, M. T. Patil, and S. K. Mehta, "Microemulsions as Nanotemplates: A Soft and Versatile Approach," in Microemulsion—Chemical Nanoreactor, 2019. [Online]. Available: [Not Available]

80. A. Beloqui, A. del Pozo-Rodríguez, A. Isla, A. Rodríguez-Gascón, and M. Á. Solinís, "Nanostructured Lipid Carriers as Oral Delivery Systems for Poorly Soluble Drugs," J. Drug Delivery Sci. Technol., vol. 42, pp. 144–154, 2017. [Online]. Available: https://doi.org/10.1016/j.jddst.2017.06.013

81. Beloqui, M. Á. Solinís, A. D. Rieux, V. Préat, and A. Rodríguez-Gascón, " Dextran-Protamine Coated Nanostructured Lipid Carriers as Mucus-Penetrating Nanoparticles for Lipophilic Drugs," Int. J. Pharm., vol. 468, pp. 105–111, 2014. [Online]. Available: https://doi.org/10.1016/j.ijpharm.2014.04.027

82. V. Kaithwas, C. P. Dora, V. Kushwah, and S. Jain, "Nanostructured Lipid Carriers of Olmesartan Medoxomil with Enhanced Oral Bioavailability," Colloids Surf., B, vol. 154, pp. 10–20, 2017. [Online]. Available: https://doi.org/10.1016/j.colsurfb.2017.03.006
83. H. A. Fathi, A. Allam, M. Elsabahy, G. Fetih, and M. El-Badry, "Nanostructured Lipid Carriers for Improved Oral Delivery and Prolonged Antihyperlipidemic Effect of Simvastatin," Colloids Surf., B, vol. 162, pp. 236–245, 2018. [Online]. Available: https://doi.org/10.1016/j.colsurfb.2017.11.064
84. P. Lakhani, A. Patil, P. Taskar, E. Ashour, and S. Majumdar, "Curcumin-Loaded Nanostructured Lipid Carriers for Ocular Drug Delivery: Design Optimization and Characterization," J. Drug Delivery Sci. Technol., vol. 47, pp. 159–166, 2018. [Online]. Available: https://doi.org/10.1016/j.jddst.2018.07.010